OXFORD, England, April 21, 2015 /PRNewswire/ --
Oxfordshire-based company wins Queen's Award for Enterprise, having more than doubled its overseas sales in just 4 years.
Oxford PharmaGenesis today celebrates winning the Queen's Award for Enterprise, for Outstanding Achievement in International Trade. This local employer is the world's first HealthScience Communications consultancy, helping its clients bring new medicines to the world in areas of patient need. Having more than doubled its exports in just 4 years, from £4.0 million in 2010 to £8.9 million in 2013, approximately 90% of its income is now earned abroad.
Oxford PharmaGenesis has grown steadily through repeat business and personal recommendation since Dr Graham Shelton founded the company in 1998. It has expanded its Oxford headquarters into three listed barns in Tubney and opened London offices overlooking Trafalgar Square. Its 110 UK employees now work with pharmaceutical clients around the world: 65% of its business is from mainland Europe and 21% from the USA. Among its achievements, the company has supported its clients in delivering scientific symposia in South America, masterclasses in the Middle East, articles in Africa and research in Russia, and has also supported projects in China and Japan. To support its global client base, the company has already opened offices in Basel and Philadelphia, with more in the pipeline.
Pride in Oxford
The success of Oxford PharmaGenesis upholds the enduring power of the Oxford name. Around the world, Oxford has a reputation for high standards of science and medicine, and excellence in publishing. Dr Chris Winchester, Managing Director, comments, "Oxford also means something more - an understated commitment to excellence, to getting it right for the patients, clinicians and clients we work with every day."
Oxford PharmaGenesis anticipates creating further highly skilled jobs in the local area. Oxford offers an unrivalled pool of talented scientists and doctors with a flair for clear communication. It works hard to retain the talented people it recruits and develops, and clients value the continuity this approach provides. "Ours is a hugely satisfying company to work for, whose success is only made possible through the efforts of our high-performing teams," says Dr Richard White, Commercial Director and Honorary Research Associate at Oxford Brookes University.
As Oxford PharmaGenesis continues to grow its business around the world, Oxford will remain at the heart of the company's success. Dr Chris Winchester, Managing Director, said, "As a proudly independent company owned by Oxford-based employee shareholders, we have the freedom to make the right decisions for our company, our clients and our employees. At Oxford PharmaGenesis, we are delighted to receive this prestigious award. We are all looking forward to a visit from the Lord-Lieutenant of Oxfordshire, who will present the Grant of Appointment in June."
Notes for Editors
About the Queen's Award
- Now in its 50th anniversary year, the Queen's Award for Enterprise is the UK's highest accolade for business success, and provides an opportunity to celebrate and encourage excellence in UK business.
- Awards are made in three categories, International Trade, Innovation, and Sustainable Development, and are valid for 5 years.
- Applications are made in September each year, audited by qualified accountants and considered by an Advisory Committee that includes representatives of Government, industry and commerce, and trade unions.
- Awards are made by the Queen on the advice of the Prime Minister, and publicly announced on the Queen's birthday, 21 April.
- Winners are invited to attend a reception at Buckingham Palace in July.
- The Lord-Lieutenant of the County (the Queen's representative in Oxfordshire) will present a Grant of Appointment and crystal bowl at our Oxford headquarters later in the year.
- Approximately 160 awards are made a year, with roughly 20% of applicants being successful.
- Previous winners of a Queen's Award for International Trade include Jaguar Land Rover (2014), Hackett (2012), and the FA Premier League (2010).
About Oxford PharmaGenesis
- Oxford PharmaGenesis Ltd is an independent consultancy established in 1998 and has 110 dedicated HealthScience experts working in offices in Oxford and London, 42 of whom are educated to PhD level or above.
- The company's top 5 overseas markets are Switzerland (44% of total sales), USA (21%), Sweden (12%), Germany (7%) and France (2%). UK clients account for only 11% of sales.
- Overseas sales more than doubled in four years from £4.0 million in financial year ending 31 October 2010 to £8.9 million in year ending 31 October 2013 (up 123%). Over the same period, total sales nearly doubled from £5.1 million to £10.0 million (up 95%), and employees from 63 to 108 (up 44%).
- The company has further offices in Basel and Philadelphia which employ a further 17 people and generate in excess of an additional £2 million in sales.
- Oxford PharmaGenesis has eight specialist practices, in medical communications, publications, value demonstration, real-world evidence, regulatory, orphan drugs, policy and commercialization.
- It takes a leadership position by exhibiting and presenting at international meetings such as the International Society of Medical Publication Professionals, the International Publication Planning Association, the International Society for Pharmacoeconomics and Outcomes Research, the International Society of Pharmacoepidemiology and the World Orphan Drug Congress.
The Queen's Award for Enterprise Magazine, 2015. Available from http://www.queensawardsmagazine.com/awardwinners/search, accessed 9 April 2015
Corfield R. The small, sane voices of big pharma. Oxford Times InBusiness Magazine, 15 May 2014, page 27 Available from http://www.oxfordtimes.co.uk/business/profiles/11210021.The_small__sane_voices_of_big_pharma/; accessed 9 April 2015.
Oxford PharmaGenesis website. http://www.pharmagenesis.com/ ; accessed 9 April 2015.
For further information, please contact:
Dr Chris Winchester
Managing Director, Oxford PharmaGenesis
SOURCE Oxford PharmaGenesis